Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.32 |
| ▸ | EHMT1 | Q9H9B1 | 4/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3259837 | 0.92 | HRH4 (0.70) | HRH4KCNH2SSTR2CARM1ESR1 | |
| Toreforant SCHEMBL29378793 | 0.81 | HRH4 (1.00) | HRH4KCNH2SSTR2CARM1 | |
| Toreforant SCHEMBL1535698 | 0.81 | HRH4 (1.00) | HRH4KCNH2SSTR2CARM1 | |
| SCHEMBL3476444 | 0.81 | HRH4 (0.55) | HRH4KCNH2SSTR2CARM1 | |
| SCHEMBL2906823 | 0.80 | HRH4 (0.75) | HRH4KCNH2SSTR2CARM1 | |
| SCHEMBL602225 | 0.78 | HRH4 (0.65) | HRH4KCNH2SSTR2CARM1 | |
| SCHEMBL18824778 | 0.78 | HRH4 (0.65) | HRH4KCNH2SSTR2 | |
| Toreforant SCHEMBL16010698 | 0.77 | HRH4 (0.90) | HRH4KCNH2SSTR2 | |
| SCHEMBL17808691 | 0.77 | HRH4 (0.80) | HRH4KCNH2SSTR2CARM1 | |
| SCHEMBL2907542 | 0.77 | HRH4 (0.61) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365548-B2 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-14 | — | — | US | claimed |
| US-20150148361-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-28 | — | — | US | claimed |
| US-8598189-B2 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-03 | — | — | US | claimed |
| US-20130072510-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (US) | 2013-03-21 | — | — | US | claimed |
| US-8343989-B2 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-01 | — | — | US | claimed |
| US-20100256373-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | EDWARDS JAMES P | 2010-10-07 | — | — | US | claimed |
| EP-2007752-B1 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-18 | — | — | EP | claimed |
| US-20090137608-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | EDWARDS JAMES P | 2009-05-28 | — | — | US | claimed |
| EP-2007752-A4 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-22 | — | — | EP | claimed |
| US-7507737-B2 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-24 | — | — | US | claimed |
| EP-2007752-A2 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-31 | — | — | EP | claimed |
| WO-2007117399-A2 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | WO | claimed |
| US-20070244126-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-18 | — | — | US | claimed |
| US-9365548-B2 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-14 | — | — | US | disclosed |
| US-9365548-B2 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-14 | — | — | US | disclosed |
| US-9365548-B2 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-14 | — | — | US | disclosed |
| WO-2007117399-A2 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244126-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244126-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244126-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244126-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | HRH4 1/4885KCNH2 507/4885SSTR2 577/4885 |
| US-20090137608-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | HRH4 1/4885KCNH2 608/4885SSTR2 727/4885 |
| US-20100256373-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH2, HRH3 | HRH4 1/4885KCNH2 608/4885SSTR2 727/4885 |
| US-20150148361-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | HRH4 1/4885KCNH2 507/4885SSTR2 577/4885 |
| US-20130072510-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | HRH4 1/4885KCNH2 608/4885SSTR2 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.